Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06794775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06794775 · ClinicalTrials.gov record · last posted 2025-12-12

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Study acronym: SWE-NEO
StatusRecruiting
PhasePhase 3
Started2025-07-10
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NEO study aims to compare these two regimens, where the PD-1/CTLA-4 combination is potentially more effective, but also associated with more side effects.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2025-01-22; most recent amendment 2025-12-11. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-08-18
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT06794775
Lead Sponsor Hildur Helgadottir
Conditions Malignant Melanoma Stage III
Enrollment 128 participants
Start Date 2025-07-10
Primary Completion 2032-04-15 (estimated)
Study Completion 2032-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-12